BioCryst, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on the stock and has a $15.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tazeen Ahmad has given his Buy rating due to a combination of factors, primarily focusing on BioCryst’s strategic acquisition of Astria Therapeutics. This acquisition brings navenibart, a promising long-acting injectable for hereditary angioedema (HAE), into BioCryst’s portfolio. The ongoing Phase 3 study of navenibart, with results expected in early 2027, suggests its potential to offer less frequent dosing compared to current market leaders, which could significantly differentiate it in the HAE market.
Furthermore, BioCryst’s existing product, Orladeyo, continues to perform well, with strong revenue growth and a solid financial outlook. The company’s recent sale of its EU franchise is expected to impact short-term revenues, but management’s focus on business development and strategic growth initiatives, such as the Astria acquisition, positions BioCryst for long-term success. These factors collectively support the Buy rating with a price objective of $15.
In another report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $26.00 price target.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year.